Edition:
United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

16.32USD
28 Apr 2017
Change (% chg)

$-0.15 (-0.91%)
Prev Close
$16.47
Open
$16.45
Day's High
$16.56
Day's Low
$16.08
Volume
78,949
Avg. Vol
124,135
52-wk High
$17.19
52-wk Low
$7.20

Latest Key Developments (Source: Significant Developments)

Omeros announces additional positive data in OMS721 Phase 2 Clinical Trial
Tuesday, 18 Aug 2015 07:00am EDT 

Omeros Corporation:Announces additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies.  Full Article

Omeros Corp announces plan to file infringement suit against ANDA Filer
Monday, 17 Aug 2015 07:00am EDT 

Omeros Corp:Press release- Omeros announces plan to file infringement suit against ANDA filer.Says plans to file a patent infringement lawsuit against Par Pharmaceutical Inc and its subsidiary, par sterile products, llc.Suit in response to anda filed by par seeking FDA approval to market a generic version of Omeros' commercial drug omidria.  Full Article

Omeros Corp approved for commercialization throughout European Union and additional countries
Monday, 3 Aug 2015 07:00am EDT 

Omeros Corp:Says omidria approved for commercialization throughout the European union and additional countries.Says approval allows for the marketing of omidria in all EU member states plus Iceland, lichtenstein, and Norway.Cataract surgery and lens replacement are among the most common surgical procedures worldwide, with about 3.9 mln of them expected to be performed in Western Europe alone in 2015.  Full Article

More From Around the Web

BRIEF-Omeros reports more positive data in OMS721 phase 2 trial in renal diseases

* Omeros reports more positive data in OMS721 phase 2 trial in renal diseases